Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cal-Maine Foods

Crown Castle International

Kinder Morgan

Prudential Financial

Two Harbors Investment

Work smarter, not harder, says the adage. One way to do that is with passive income, which is derived from ownership rather than labor or active involvement in an enterprise.

Want $3750 in Passive Income? Invest $7500 in These 7 Stocks

Gilead Sciences: 2024 Catalysts Should Drive Growth And Change In Sentiment

Gilead Sciences said on Thursday enrollments to test its cancer drug, magrolimab, on solid tumors had been paused globally, a week after the U.S. regulator put some studies on hold following increased risk of patient deaths.

Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials

Amgen

AstraZeneca

Biogen

Bristol-Myers

Novartis

Sanofi

Last October, life sciences giant Thermo Fisher Scientific (NYSE: TMO ) inadvertently laid out the case for contrarian biotech stocks. According to Reuters, the company revealed that a slump in demand from the biotech sector for its services could extend into 2024.

7 Contrarian Biotech Stocks to Consider Amid Sector Weakness

bluebird bio

CRISPR Therapeutics

GoodRx Holdings

Sarepta Therapeutics

Vertex Pharmaceuticals

Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. The shot heard around the world in the medical sector occurred on December 8, 2023, when the U.S. FDA approved Casgevy, the first FDA-approved gene-editing treatment for sickle cell disease (SCD) from Vertex Pharmaceuticals Inc. NASDAQ: VRTX and co-developed by CRISPR Therapeutics AG NASDAQ: CRSP.

Gene therapy: Why does it cost millions for a single treatment?

VanEck Vectors Biotech ETF

iShares Nasdaq Biotechnology ETF

Invesco Dynamic Biotechnology & Genome ETF

SPDR S&P Biotech ETF

Look into how Biotech ETFs performed after Q4 earnings.

Where Are Biotech ETFs Headed After Q4 Earnings?

Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.

Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline

Agilent Technologies

C.H. Robinson Worldwide

Core Laboratories Inc

Comcast

Compass Minerals

Campbell Soup

Corteva Inc

Estee Lauder

Etsy

Huntington Ingalls Industries

Hilton Worldwide Holdings

Harley-Davidson

Honeywell

International Flavors & Fragrances

InterContinental Hotels Group

Kenvue

Lockheed Martin

Marriott

McDonald's

MarketAxess Holdings

Altria

NIKE

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).

U.S. Wide-Moat Stocks On Sale - The February 2024 Heat Map

CymaBay Therapeutics

Shares of CymaBay Therapeutics (CBAY) soared to an all-time high Monday after Gilead Sciences (GILD) announced it's buying the developer of medicine for liver and other chronic diseases for $4.3 billion.

Why Gilead Sciences Is Buying CymaBay Therapeutics for $4.3 Billion

CymaBay Therapeutics shares jumped nearly 25% and hit a new record high in early trading after the clinical-stage biopharmaceutical company agreed to be acquired by Gilead Sciences for $4.3 billion.

CymaBay Therapeutics Shares Hit All-Time High on Gilead Deal

CymaBay Therapeutics Inc (NASDAQ: CBAY) opened more than 25% up this morning after Gilead Sciences Inc (NASDAQ: GILD) said it will buy the biopharmaceutical company for $4.3 billion. Details of Gilead-CymaBay agreement The said deal values CymaBay at $32.50 per share.

Gilead to buy CymaBay Therapeutics for $4.3 billion

CymaBay stock skyrocketed Monday after Gilead Sciences announced it will buy it for $4.3 billion. CBAY stock surged almost 25%.

CymaBay Stock Rockets After Gilead Sciences Unveils $4.3 Billion Acquisition

Gilead Sciences on Monday said it will acquire CymaBay Therapeutics for $4.3 billion, to expand its portfolio of liver disease drugs.

Drugmaker Gilead to acquire CymaBay for $4.3 bln

Gilead Sciences Inc. GILD, -0.18% said Monday it has reached a deal to acquire CymaBay Therapeutics Inc. CBAY, +2.92% for $32.50 per share in cash, a 27% premium to CymaBay's closing price Friday, for a total deal equity value of $4.3 billion. CymaBay's lead asset is seladelpar, an investigational treatment for primary biliary cholangitis, a type of liver disease that causes bile-duct damage.

Gilead strikes deal to acquire CymaBay for $4.3 billion

FOSTER CITY, Calif. & NEWARK, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay's investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead's existing liver portfolio and aligns wit.

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has been named one of America's Most JUST Companies. The ranking, presented by JUST Capital and CNBC, reflects Gilead's longstanding commitment to operate responsibly by prioritizing stakeholder engagement – including with the patients and communities the company serves, employees and shareholders – while working to create a healthier world for all people. Gilead was recognized on the top 100.

Gilead Named One of America's Most JUST Companies by JUST Capital and CNBC

BIOLASE

CNS Pharmaceuticals

Revelation Biosciences

Zai Lab Ltd.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Are Preparing To Pump In February

Agios Pharmaceuticals

Alkermes

Arrowhead Pharmaceuticals

BioMarin Pharmaceutical

Unlike many other market segments, biotech stocks stand out for their direct relevance. For example, investors who typically wager on aerospace and defense plays usually aren't fighter pilots.

7 Biotech Stocks Fighting America's Deadliest Diseases

Kyverna Therapeutics Inc

Shares of Kyverna Therapeutics jumped 55.7% in their market debut on Thursday, giving the biopharmaceutical company that is backed by Gilead Sciences a market capitalization of $1.4 billion.

Gilead-backed Kyverna Therapeutics valued at $1.4 bln in stellar debut

Gilead delivered a mixed fourth quarter relative to expectations. The biopharma giant also issued underwhelming forward guidance.

Why Gilead Sciences Stock Dropped Today

Mastercard

Zoetis

Keurig Dr Pepper Inc

Mastercard today announced that its Board of Directors has declared a quarterly cash dividend of 66 cents per share. The cash dividend will be paid on May 9, 2024 to holders of record of its Class A common stock and Class B common stock as of April 9, 2024.

Daily Dividend Report: Mastercard, MMM, Gilead, Keurig, Zoetis

Gilead (GILD) posts mixed results for the fourth quarter. Sales beat estimates on the better-than-expected performance of Veklury due to higher hospitalizations at the end of 2023.

Gilead (GILD) Q4 Earnings Miss Estimates, Sales Top on Veklury

Gilead Sciences said the U.S. Food and Drug Administration had put trials of its blood cancer drug on hold after it was tied to an increase in risk of death in a late-stage study.

US FDA puts hold on Gilead's blood cancer therapy trials

News for Gilead Sciences Stock (GILD)